Lee J, Jang H, Kang SH, Kim J, Kim JS, Kim JP, et al. Cerebrospinal fluid biomarkers for the diagnosis and classification of Alzheimer’s disease spectrum. J Korean Med Sci. 2020;35:e361.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fandos N, Perez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, et al. Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017;8:179–87.
Article
PubMed
PubMed Central
Google Scholar
Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66:23–9.
Article
CAS
PubMed
Google Scholar
Hernandez-Guillamon M, Delgado P, Penalba A, Rodriguez-Luna D, Molina CA, Rovira A, et al. Plasma beta-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. Neurodegener Dis. 2012;10:320–3.
Article
CAS
PubMed
Google Scholar
Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841–9.
Article
PubMed
PubMed Central
Google Scholar
Pesini P, Perez-Grijalba V, Monleon I, Boada M, Tarraga L, Martinez-Lage P, et al. Reliable measurements of the beta-amyloid pool in blood could help in the early diagnosis of AD. Int J Alzheimers Dis. 2012;2012:604141.
PubMed
PubMed Central
Google Scholar
Risacher SL, Fandos N, Romero J, Sherriff I, Pesini P, Saykin AJ, et al. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. Alzheimers Dement (Amst). 2019;11:510–9.
Article
Google Scholar
Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647–e59.
CAS
PubMed
PubMed Central
Google Scholar
Shanthi KB, Krishnan S, Rani P. A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer’s disease. SAGE Open Med. 2015;3:2050312115598250.
Article
PubMed
PubMed Central
Google Scholar
Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease–related β-amyloid status. JAMA neurology. 2019;76:1060–9.
Article
PubMed
PubMed Central
Google Scholar
Verberk IM, Slot RE, Verfaillie SC, Heijst H, Prins ND, van Berckel BN, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84:648–58.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554:249–54.
Article
CAS
PubMed
Google Scholar
Roberts KF, Elbert DL, Kasten TP, Patterson BW, Sigurdson WC, Connors RE, et al. Amyloid-β efflux from the central nervous system into the plasma. Ann Neurol. 2014;76:837–44.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, et al. Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids and Barriers of the CNS. 2011;8:1–11.
Article
CAS
Google Scholar
Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333–44.
Article
CAS
PubMed
Google Scholar
Donahue JE, Johanson CE. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol. 2008;67:261–70.
Article
CAS
PubMed
Google Scholar
Keshavan A, Pannee J, Karikari TK, Rodriguez JL, Ashton NJ, Nicholas JM, et al. Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70. Brain. 2021;144:434–49.
PubMed
PubMed Central
Google Scholar
Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain. 2016;139:1226–36.
Article
PubMed
PubMed Central
Google Scholar
Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol. 2015;78:439–53.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pietroboni AM, Scarioni M, Carandini T, Basilico P, Cadioli M, Giulietti G, et al. CSF β-amyloid and white matter damage: a new perspective on Alzheimer’s disease. Journal of Neurology, Neurosurgery &. Psychiatry. 2018;89:352–7.
Google Scholar
Kang SH, Park YH, Lee D, Kim JP, Chin J, Ahn Y, et al. The cortical neuroanatomy related to specific neuropsychological deficits in Alzheimer’s continuum. Dement Neurocogn Disord. 2019;18:77–95.
Article
PubMed
PubMed Central
Google Scholar
Ahn HJ, Chin J, Park A, Lee BH, Suh MK, Seo SW, et al. Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci. 2010;25:1071–6.
Article
PubMed
PubMed Central
Google Scholar
Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol. 2007;27:22–31.
Article
PubMed
Google Scholar
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.
Article
PubMed
PubMed Central
Google Scholar
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.
Article
CAS
PubMed
Google Scholar
Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43:1683–9.
Article
CAS
PubMed
Google Scholar
Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74:1346–50.
Article
CAS
PubMed
PubMed Central
Google Scholar
Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston Criteria. Stroke. 2018;49:491–7.
Article
PubMed
PubMed Central
Google Scholar
Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol. 2011;7:1–9.
Article
PubMed
PubMed Central
Google Scholar
Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Annals of neurology. 2007;62:229–34.
Article
PubMed
Google Scholar
Kim HJ, Yang JJ, Kwon H, Kim C, Lee JM, Chun P, et al. Relative impact of amyloid-beta, lacunes, and downstream imaging markers on cognitive trajectories. Brain. 2016;139:2516–27.
Article
PubMed
Google Scholar
Jang H, Jang YK, Kim HJ, Werring DJ, Lee JS, Choe YS, et al. Clinical significance of amyloid beta positivity in patients with probable cerebral amyloid angiopathy markers. Eur J Nucl Med Mol Imaging. 2019;46:1287–98.
Article
CAS
PubMed
Google Scholar
Kim SE, Woo S, Kim SW, Chin J, Kim HJ, Lee BI, et al. A nomogram for predicting amyloid PET positivity in amnestic mild cognitive impairment. J Alzheimers Dis. 2018;66:681–91.
Article
CAS
PubMed
Google Scholar
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.
Article
CAS
PubMed
Google Scholar
Park JH, Seo SW, Kim C, Kim SH, Kim GH, Kim ST, et al. Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiol Aging. 2014;35:254–60.
Article
CAS
PubMed
Google Scholar
Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59:1152–60.
Article
PubMed
Google Scholar
Kim H-R, Choe YS, Moon SH, Kim HJ, Jang H, L.Na D, et al. Finding the optimal cutoff value for amyloid β positivity using the iterative outlier method and concordance rate. Precis Future Med. 2021;0.
Cho SH, Choe YS, Kim YJ, Lee B, Kim HJ, Jang H, et al. Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments. Sci Rep. 2020;10:19576.
Article
CAS
PubMed
PubMed Central
Google Scholar
Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1–15 e1-4.
Article
PubMed
Google Scholar
Cho SH, Choe YS, Kim HJ, Jang H, Kim Y, Kim SE, et al. A new Centiloid method for (18)F-florbetaben and (18)F-flutemetamol PET without conversion to PiB. Eur J Nucl Med Mol Imaging. 2020;47:1938–48.
Article
CAS
PubMed
Google Scholar
Amadoru S, Doré V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease. Alzheimers Res Ther. 2020;12:22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonca A, Otto M, et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. Brain. 2016;139:2540–53.
Article
PubMed
PubMed Central
Google Scholar
Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer’s disease. Brain. 2015;138:772–83.
Article
PubMed
Google Scholar
Reimand J, de Wilde A, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, et al. PET and CSF amyloid-beta status are differently predicted by patient features: information from discordant cases. Alzheimers Res Ther. 2019;11:100.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vos SJB, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging. 2016;44:1–8.
Article
PubMed
PubMed Central
Google Scholar
Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, Zanette M, et al. Post-mortem histopathology underlying beta-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun. 2016;4:130.
Article
PubMed
PubMed Central
CAS
Google Scholar
Selnes P, Blennow K, Zetterberg H, Grambaite R, Rosengren L, Johnsen L, et al. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res. 2010;7:10.
Article
PubMed
PubMed Central
CAS
Google Scholar
van Westen D, Lindqvist D, Blennow K, Minthon L, Nagga K, Stomrud E, et al. Cerebral white matter lesions - associations with Abeta isoforms and amyloid PET. Sci Rep. 2016;6:20709.
Article
PubMed
PubMed Central
CAS
Google Scholar
Hilal S, Akoudad S, van Duijn CM, Niessen WJ, Verbeek MM, Vanderstichele H, et al. Plasma amyloid-beta levels, cerebral small vessel disease, and cognition: the Rotterdam Study. J Alzheimers Dis. 2017;60:977–87.
Article
CAS
PubMed
Google Scholar
Charidimou A, Friedrich JO, Greenberg SM, Viswanathan A. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: a meta-analysis. Neurology. 2018;90:e754–e62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Renard D, Castelnovo G, Wacongne A, Le Floch A, Thouvenot E, Mas J, et al. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. J Neurol. 2012;259:2429–33.
Article
CAS
PubMed
Google Scholar
Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol. 2009;66:245–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chatterjee P, Tegg M, Pedrini S, Fagan AM, Xiong C, Singh AK, et al. Plasma amyloid-beta levels in a pre-symptomatic Dutch-type hereditary cerebral amyloid angiopathy pedigree: a cross-sectional and longitudinal investigation. Int J Mol Sci. 2021;22.
Bornebroek M, De Jonghe C, Haan J, Kumar-Singh S, Younkin S, Roos R, et al. Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. Neurobiol Dis. 2003;14:619–23.
Article
CAS
PubMed
Google Scholar
van Etten ES, Verbeek MM, van der Grond J, Zielman R, van Rooden S, van Zwet EW, et al. β-Amyloid in CSF: biomarker for preclinical cerebral amyloid angiopathy. Neurology. 2017;88:169–76.
Article
PubMed
PubMed Central
CAS
Google Scholar